Alpha radionuclide-chelated radioimmunotherapy promoters enable local radiotherapy/chemodynamic therapy to discourage cancer progression

BACKGROUND: Astatine-211 is an α-emitter with high-energy α-ray and high cytotoxicity for cancer cells. However, the targeted alpha therapy (TAT) also suffers from insufficient systematic immune activation, resulting in tumor metastasis and relapse. Combined immune checkpoint blockade (ICB) with che...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jiajia, Li, Feize, Yin, Yuzhen, Liu, Ning, Zhu, Mengqin, Zhang, Han, Liu, Weihao, Yang, Mengdie, Qin, Shanshan, Fan, Xin, Yang, Yuanyou, Zhang, Kun, Yu, Fei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9461185/
https://www.ncbi.nlm.nih.gov/pubmed/36076298
http://dx.doi.org/10.1186/s40824-022-00290-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9461185/
https://www.ncbi.nlm.nih.gov/pubmed/36076298
http://dx.doi.org/10.1186/s40824-022-00290-6

Ejemplares similares